Ashish Kamat: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Ashish Kamat, Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD Anderson Cancer Center posted on X:
“Agree: efficacy plus ease of scheduling likely to make this attractive option for patients.
Also agree – time to move beyond single arm studies and on to RCTs as we state in IBCG consensus paper.”
Title: Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Authors: Roger Li, Patrick J. Hensley, Shilpa Gupta, Hikmat Al-Ahmadie, Marko Babjuk, Peter C. Black, Maurizio Brausi, Kelly K. Bree, Mario I. Fernández, Charles C. Guo, Amir Horowitz, Donald L. Lamm, Seth P. Lerner, Yair Lotan, Paramananthan Mariappan, David McConkey, Laura S. Mertens, Carmen Mir, Jeffrey S. Ross, Michael O’Donnell, Ashish M. Kamat
Read The Full Article on Science Direct.
More posts featuring Bladder Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023